Rate Video

VJVirtual | Prognostic value of the SPOP mutant genomic subclass in prostate cancer

Eric Klein • 3 Apr 2020

Genitourinary Cancer Prostate Cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, reviews a publication he co-authored on the prognostic value of SPOP mutant genomic subclass in prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Genomic testing: a precision-medicine approach applied to early-stage prostate cancer

Eric Klein • 5 Jun 2016

Polygenic risk scores for the early detection of prostate cancer

Eric Klein • 18 Oct 2022

Clinicopathologic models in prostate cancer: impact of a 22-gene genomic classifier

Eric Klein • 3 Apr 2020

Sensitive and specific multi-cancer detection

Eric Klein • 6 Apr 2020

Related Videos

Challenges of nmCRPC management: to treat or not?

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Cabozantinib plus docetaxel and prednisone in mCRPC

Munjid Al Harthy

How to involve patients in clinical decision making